Cell
AssigneesUCL Business PLC, Autolus Limited
InventorsMartin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
Life of this patent
Estimating the term…
Abstract
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
Claims4
A method for treating a cancerous disease, which comprises the step of administering a pharmaceutical composition which comprises a plurality of T cells or natural killer cells to a subject, wherein the T cells or natural killer cells express a chimeric antigen receptor (CAR) comprising a CD22-binding domain which comprises:
- a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:
- CDR1
- (SEQ ID NO:
- 27)
- NYWIN,
- CDR2
- (SEQ ID NO:
- 28)
- NIYPSDSFTNYNQKFKD,
- and
- CDR3
- (SEQ ID NO:
- 29)
- DTQERSWYFDV;
- and
- b) a light chain variable region (VL) having CDRs with the following sequences:
- CDR1
- (SEQ ID NO:
- 30)
- RSSQSLVHSNGNTYLH,
- CDR2
- (SEQ ID NO:
- 31)
- KVSNRFS,
- and
- CDR3
- (SEQ ID NO:
- 32)
- SQSTHVPWT,
- wherein cancer cells of the cancerous disease express CD22.
Dependencies are inferred from the claim text.